Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03111381 · ClinicalTrials.gov registry record · Phase 2
Toradol to Reduce Ureteroscopic Symptoms Trial
A Phase 2 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 2
- Development phase
- 94
- Enrollment target
NCT03111381 is a Phase 2 study that has completed, run by Yale University. The registered enrollment target is 94 participants.
The verdict
NCT03111381, a Phase 2 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 94 participants
- Enrollment target
Study Summary
Double blinded randomized controlled clinical trial to assess the impact of intraoperative Toradol on post-operative pain scores for patients undergoing ureteroscopy for urinary stone management.
Interventions
- DRUG Toradol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 94 participants |
| Start Date | 2017-08-01 |
| Est. Completion | 2020-06-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03111381
The ClinicalTrials.gov registry entry for NCT03111381 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 94 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Toradol is the first listed.
NCT03111381 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03111381 about?
NCT03111381 is a clinical study titled "Toradol to Reduce Ureteroscopic Symptoms Trial". Double blinded randomized controlled clinical trial to assess the impact of intraoperative Toradol on post-operative pain scores for patients undergoing ureteroscopy for urinary stone management.
What is the current status of trial NCT03111381?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 94 participants. The study started on 2017-08-01. Estimated completion is 2020-06-01.
What interventions are being tested in trial NCT03111381?
The interventions under investigation include: Toradol (DRUG).
Who is sponsoring clinical trial NCT03111381?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.